Breaking News Instant updates and real-time market news.

AMZN

Amazon.com

$992.27

4.69 (0.47%)

, GOOG

Alphabet

$929.36

1.4 (0.15%)

10:25
08/08/17
08/08
10:25
08/08/17
10:25

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN), Alphabet (GOOG, GOOGL), and Facebook (FB) were reinstated with a Buy at Mizuho, while eBay (EBAY) and Twitter (TWTR) were reinstated with an Underperform. 2. Broadridge (BR) initiated with a Neutral at DA Davidson. 3. Brighthouse Financial (BHF) initiated with an Overweight at Barclays. 4. Akcea Therapeutics (AKCA) WAS initiated with an Outperform at BMO Capital and Cowen, an Outperform at Wells Fargo, as well as a Buy at Stifel. 5. Lockheed Martin (LMT) and Raytheon (RTN) were initiated with an Overweight at Morgan Stanley, while Northrop Grumman (NOC) was initiated with an Equal Weight, and General Dynamics (GD) was initiated with an Underweight at the firm. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

AMZN

Amazon.com

$992.27

4.69 (0.47%)

GOOG

Alphabet

$929.36

1.4 (0.15%)

GOOGL

Alphabet Class A

$945.75

-0.04 (-0.00%)

FB

Facebook

$171.98

2.36 (1.39%)

EBAY

eBay

$36.11

0.49 (1.38%)

TWTR

Twitter

$16.06

-0.34 (-2.07%)

BR

Broadridge

$75.19

-0.4127 (-0.55%)

BHF

Brighthouse Financial

$61.72

-2.85 (-4.41%)

AKCA

Akcea Therapeutics

$14.90

-0.09 (-0.60%)

LMT

Lockheed Martin

$299.44

2.29 (0.77%)

RTN

Raytheon

$174.42

0.91 (0.52%)

NOC

Northrop Grumman

$269.95

0.37 (0.14%)

GD

General Dynamics

$200.54

-0.6 (-0.30%)

  • 08

    Aug

  • 10

    Aug

  • 16

    Aug

  • 18

    Aug

  • 23

    Aug

  • 13

    Sep

AMZN Amazon.com
$992.27

4.69 (0.47%)

08/08/17
MKMP
08/08/17
NO CHANGE
Target $1275
MKMP
Buy
Amazon price target raised to $1,275 from $1,095 at MKM Partners
MKM Partners analyst Rob Sanderson raised his revenue outlook for Amazon.com, noting that units fulfilled are growing much faster than commerce revenue and subscription revenue growth, a proxy for Prime adoption, grew by over 50% again in Q2. While he does not expect Amazon will generate meaningful profits anytime soon, he also believes investors have become "very comfortable" with the company's continued investments. Until investors can see a limit on growth opportunities, revenue growth and share gain will matter more than profitability, said Sanderson, who raised his price target on Amazon shares to $1,275 from $1,095.
08/08/17
WELS
08/08/17
NO CHANGE
WELS
Food distributors outlook positive into June quarter results, says Wells Fargo
Wells Fargo says that sentiment on the food distributors has deteriorated due to worries about inflation and Amazon's (AMZN)possible entry into the space. However, the firm thinks that inflation is "a net positive" for the sector, while the three largest companies in the sector look set to benefit from share gains and M&A accretion. Wells is most upbeat on US Foods (USFD)and Sysco (SYY), citing reductions in their valuation and their efforts to increase volume and margins. Wells thinks the stocks have reached attractive entry points as it believes that investors are exaggerating the Amazon threat. It keeps Outperform ratings on US Foods and Sysco.
08/08/17
08/08/17
INITIATION
Target $1250

Buy
Amazon.com reinstated with a Buy at Mizuho
As previously reported, Mizuho analyst James Lee reinstated Amazon with a Buy rating, stating that he sees the next pillar of growth likely coming from advertising through voice search to allow brands to sell directly to consumers. The analyst, who sees Amazon having many levers to harness its monetization potential, set a $1,250 price target on the stock.
08/07/17
MZHO
08/07/17
INITIATION
Target $1250
MZHO
Buy
Amazon.com reinstated with a Buy at Mizuho
Mizuho analyst James Lee reinstated Amazon with a Buy and a $1,250 price target.
GOOG Alphabet
$929.36

1.4 (0.15%)

07/31/17
PIVT
07/31/17
DOWNGRADE
Target $140
PIVT
Sell
Facebook downgraded to Sell from Hold at Pivotal Research
Pivotal Research analyst Brian Wieser downgraded Facebook (FB) to Sell with an unchanged price target of $140. The social network closed Friday up $2.01 to $172.45. The shares are not factoring in risks to the company's growth following their "remarkable run" this year, Wieser tells investors in a research note. The recent European Commission ruling on Google (GOOG, GOOGL) Shopping and the agency's approach to dominant companies in general poses a greater risk as Facebook becomes larger, the analyst contends.
08/08/17
PIPR
08/08/17
NO CHANGE
Target $1050
PIPR
Overweight
Alphabet shares remain undervalued, says Piper Jaffray
Piper Jaffray analyst Samuel Kemp says his firm's proprietary browser mix regression model suggests that if mobile does not slow its pace, investors could expect Google Websites' traffic acquisition costs to be 15% of gross Websites revenue by 2020 versus the 11% today. The analyst believes investors remain concerned over the continued rise of Google Websites' traffic acquisition costs. TAC, "while a profit headwind, is not enough to outweigh the long-term upside potential," Kemp tells investors in a research note. He says the analysis resulted in "minuscule adjustments" to his estimates and reinforces his belief that Alphabet remains undervalued. Kemp has an Overweight rating on the shares with a $1,050 price target.
08/08/17
08/08/17
INITIATION
Target $1220

Buy
Alphabet reinstated with a Buy at Mizuho
As previously reported, Mizuho analyst James Lee reinstated Alphabet with a Buy rating, stating that the company is benefiting from positive online advertising secular trends while closing the monetization gap of mobile to PC with new technologies. The analyst, who sees many levers for Alphabet to harness its monetization potential, set a $1,220 price target on the shares.
08/04/17
RHCO
08/04/17
NO CHANGE
RHCO
Yelp results 'very encouraging,' says SunTrust
After Yelp (YELP) delivered beat and raise results, SunTrust analyst Matthew Thornton calls its earnings "very encouraging." He says that the company's engagement was up while its dependency on Google (GOOG, GOOGL) fell. He raised his price target on Yelp to $44 from $35 and keeps a Buy rating.
GOOGL Alphabet Class A
$945.75

-0.04 (-0.00%)

08/07/17
MZHO
08/07/17
INITIATION
Target $1220
MZHO
Buy
Alphabet initiated with a Buy at Mizuho
Mizuho analyst James Lee reinstated Alphabet with a Buy and a $1,220 price target.
FB Facebook
$171.98

2.36 (1.39%)

08/08/17
08/08/17
INITIATION
Target $230

Buy
Facebook reinstated with a Buy at Mizuho
As previously reported, Mizuho analyst James Lee reinstated Facebook with a Buy and a $230 price target, arguing that the company has the "unique advantage" of both pricing leverage due to its highly engaging ad formats and best-in-class targeting paired with inventory leverage due to ad formats and data that span its core Facebook, Instagram and mobile messaging properties.
07/31/17
07/31/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Facebook (FB) downgraded to Sell from Hold at Pivotal Research with analyst Brian Wieser saying the shares are not factoring in risks to the company's growth following their "remarkable run" this year. 2. Ulta Beauty (ULTA) downgraded to Perform from Outperform at Oppenheimer with analyst Rupesh Parikh saying softer commentary from L'Oreal on its earnings call, increasing promotional activity from the department store channel, and more difficult year-over-year comparisons "could now signal a potentially more challenging beauty backdrop going forward." 3. Hertz (HTZ) downgraded to Underweight from Equal Weight at Barclays with analyst Brian Johnson saying fundamentals may have bottomed, but the stock is ignoring the challenges ahead in the company's earnings recovery following the nearly 100% rally since June 21. 4. Citi (C) downgraded to Market Perform from Outperform at BMO Capital with analyst James Fotheringham citing valuation and lack of catalysts. 5. Visteon (VC) downgraded to Neutral from Buy at UBS with analyst Colin Langan saying the risk/reward is more balanced with the shares up 60% over the last year. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/07/17
MZHO
08/07/17
INITIATION
Target $230
MZHO
Facebook reinstated with a Buy at Mizuho
Mizuho analyst James Lee reinstated Facebook with a Buy and a $230 price target.
08/07/17
MKMP
08/07/17
NO CHANGE
MKMP
Facebook price target rasied to $200 from $180 at MKM Partners
MKM Partners analyst Rob Sanderson raised his price target on Facebook as he thinks there is "an upward bias" to the stock's valuation. He keeps a Buy rating on the shares.
EBAY eBay
$36.11

0.49 (1.38%)

07/21/17
BARD
07/21/17
NO CHANGE
Target $38
BARD
Outperform
eBay results show platform initiatives remain on track, says Baird
Baird analyst Colin Sebastian noted eBay reported solid Q2 results, which suggests its platform initiatives remain on track. He noted an acceleration in core Marketplace performance, growth in new buyers and buying activity, improved seller activity, and management's reiteration of guidance. Sebastian reiterated his Outperform rating on eBay shares.
08/07/17
MZHO
08/07/17
INITIATION
Target $34
MZHO
Underperform
eBay reinstated with an Underperform at Mizuho
Mizuho analyst James Lee reinstated eBay with an Underperform and a $34 price target.
07/21/17
UBSW
07/21/17
NO CHANGE
Target $42
UBSW
Buy
eBay results demonstrating improving user growth, engagement, says UBS
UBS analyst Eric Sheridan noted eBay reported solid results for the third quarter in a row by demonstrating improving engagement trends, stable to improving conversion, improved returns on investment, and re-accelerating user growth. Sheridan reiterated his Buy rating and raised his price target to $42 from $38 on eBay shares.
07/13/17
BARD
07/13/17
NO CHANGE
Target $38
BARD
Outperform
eBay appears to end Q2 on positive note, says Baird
Baird analyst Colin Sebastian sees room for upside in Q2 estimates for eBay as the firm's proprietary tracker showed some acceleration in growth relative to May - from mid/high single digits into low double digits. The analyst said data also showed U.K. online spending trends suggested June improvement as well. Sebastian reiterated his Outperform rating and $38 price target on eBay shares.
TWTR Twitter
$16.06

-0.34 (-2.07%)

07/27/17
BARD
07/27/17
NO CHANGE
BARD
Neutral
Twitter lack of user growth remains concerning, says Baird
Baird analyst Colin Sebastian said Twitter's Q2 report shows that its user engagement and cost control initiatives are showing signs of progress, but he believes the company's lack of user growth remains concerning. The company's guidance "once again appears conservative," though it will be facing tough comps in coming quarters, added Sebastian, who keeps a Neutral rating on Twitter shares.
07/27/17
MONN
07/27/17
NO CHANGE
MONN
Neutral
Twitter may have further downside risk of 25%, says Monness Crespi
Monness Crespi analyst James Cakmak said is still unconvinced on Twitter's strategy and prospects and said the election cycle was a "one-time gift." Cakmak thinks Twitter has the most compelling real time content in the world, but cannot extract value from what is already there and is in "limbo" on in deciding how to execute on DAU growth and trying to be everything to everyone. The analyst maintained a Neutral rating but sees further downside risk by about 25%, even following today's selloff.
07/24/17
WEDB
07/24/17
NO CHANGE
Target $16
WEDB
Neutral
Twitter price target raised to $16 from $14 at Wedbush
Wedbush analyst Michael Pachter raised his price target for Twitter to $16 and keeps a Neutral rating on the shares ahead of the company's Q2 results on July 27. The recent reacceleration of user growth and an improving user experience are "positive signs," Pachter tells investors in a research note titled "Empty Nest-Waiting for Twitter to Start Building its Family Again." The analyst, however, thinks advertisers will devote their ad budgets to platforms with better targeting, reach, and scale until Twitter can return to revenue growth. He expects Twitter to report "underwhelming" user growth and cost per engagement trends.
08/07/17
MZHO
08/07/17
INITIATION
Target $14.5
MZHO
Underperform
Twitter reinstated with an Underperform at Mizuho
Mizuho analyst James Lee reinstated Twitter with an Underperform and a $14.50 price target.
BR Broadridge
$75.19

-0.4127 (-0.55%)

11/04/16
11/04/16
NO CHANGE

Broadridge acquires M&O Systems
Broadridge Financial acquired M&O Systems, a provider of advisor compensation management solutions that help broker-dealers and wealth management firms support advisors and grow their businesses. Terms of the deal were not disclosed. With this acquisition, Broadridge expands its wealth offerings to include advisor compensation and incentive management, advisor commission portal, account opening and client books and records solutions. M&O Systems will be rebranded as Broadridge Advisor Compensation solutions.
09/29/16
SDLR
09/29/16
DOWNGRADE
SDLR
Hold
Broadridge downgraded to Hold from Buy at Sandler O'Neill
Sandler O'Neill analyst Christopher Donat downgraded Broadridge to Hold based on valuation.
08/07/17
DADA
08/07/17
INITIATION
Target $74
DADA
Neutral
Broadridge initiated with a Neutral at DA Davidson
DA Davidson analyst Peter Heckmann started Broadridge Financial Solutions with a Neutral rating and $74 price target. The analyst views the risk/reward as balanced at current share levels
11/28/16
MSCO
11/28/16
NO CHANGE
MSCO
Softline Black Friday weekend sales mixed versus last year, says Morgan Stanley
Morgan Stanley said overall Softline Black Friday weekend sales were mixed verus last year saying L Brands (LB), lululemon (LULU), and Hollister were weekend winners and Gap (GPS), Broadridge (BR), Michael Kors (KORS), and Anthro were laggards.
BHF Brighthouse Financial
$61.72

-2.85 (-4.41%)

08/07/17
SBSH
08/07/17
INITIATION
Target $50
SBSH
Sell
Brighthouse Financial initiated with a Sell at Citi
Citi analyst Suneet Kamath started Brighthouse Financial with a Sell rating and $50 price target. The analyst sees an unfavorable risk/reward profile given his sum-of-the-parts analysis. Brighthouse's "sizable" below-the-line-charges will result in near-term economic earnings and returns on equity that are "much lower than operating statistics," the analyst contends.
08/08/17
LEHM
08/08/17
INITIATION
Target $72
LEHM
Overweight
Brighthouse Financial initiated with an Overweight at Barclays
Barclays analyst Jay Gelb started Brighthouse Financial with an Overweight rating and $72 price target. The current valuation is "seems too cheap to ignore," the analyst contends. He believes investor sentiment is already unfavorable with potential to improve.
08/07/17
08/07/17
INITIATION
Target $72

Market Perform
Brighthouse Financial initiated with a Market Perform at FBR Capital
FBR Capital analyst Randy Binner started Brighthouse Financial with a Market Perform rating and $72 price target. The analyst sees a balanced risk/reward at current share levels.
08/07/17
08/07/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. XPO Logistics (XPO) resumed with an Outperform at William Blair. 2. BlackBerry (BBRY) reinstated with a Sell at Goldman Sachs. 3. Brighthouse Financial (BHF) was initiated with a Sell at Citi, a Market Perform at Keefe Bruyette, FBR Capital, and Wells Fargo, a Sector Perform at RBC Capital, and a Neutral at Credit Suisse. 4. Zoetis (ZTS) reinstated with a Neutral at Goldman Sachs. 5. BeiGene (BGNE) initiated with a Buy at Ladenburg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
AKCA Akcea Therapeutics
$14.90

-0.09 (-0.60%)

08/08/17
WELS
08/08/17
INITIATION
Target $27
WELS
Outperform
Akcea Therapeutics initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started Akcea Therapeutics with an Outperform rating and $27 price target. The analyst sees potential blockbuster opportunity for the company's lead antisense oligonucleotide therapeutic volanesorsen in patients with familial chylomicronemia syndrome and other severe lipid disorders.
08/08/17
BMOC
08/08/17
INITIATION
BMOC
Outperform
Akcea Therapeutics initiated with an Outperform at BMO Capital
BMO Capital analyst Do Kim started coverage of Akcea with a $25 price target and an Outperform rating. The analyst says the company provides "a commercial-ready, rare disease drug opportunity, with a validating partnership lead candidate" at a "small-cap valuation." Kim predicts that the company's volanesorsen, a triglyceride-lowering drug being developed for two rare, severe genetic disorders, Familial Chylomicronemia Syndrome and Familial Partial Lipodystrophy, will be approved as a treatment for FCS in 2H18 and generate worldwide peak sales of $800M.
08/08/17
COWN
08/08/17
INITIATION
COWN
Outperform
Akcea Therapeutics initiated with an Outperform at Cowen
Cowen analyst Eric Schmidt initiated Akcea Therapeutics with an Outperform saying lead candidate volanesorsen, a triglyceride-lowering drug being developed for two rare, severe genetic disorders, Familial Chylomicronemia Syndrome and Familial Partial Lipodystrophy, has demonstrated unparalleled potency at reducing serum triglycerides in Phase III trials in patients with severe hypertriglyceridemia. The analyst sees $500M+ in peak sales potential for volanesorsen in Familial Chylomicronemia Syndrome and expects shares to move higher as investors gain conviction in this commercial outlook and the rest of the clinical pipeline.
08/08/17
STFL
08/08/17
INITIATION
Target $19
STFL
Buy
Akcea Therapeutics initiated with a Buy at Stifel
Stifel analyst Stephen Willey initiated Akcea Therapeutics with a Buy and a $19 price target saying it provides investors with exposure to both a clinically de-risked lead candidate, volanesorsen, in greater than1 rare disease and an earlier-stage, mostly first-in-class product pipeline directed against genetically-validated targets of cardiovascular disease. The analyst believes the overall risk/reward profile, increasingly flexible FDA, and management's monitoring/labeling concessions improve our confidence into second half 2018 FDA/EMA approvals and assumes volanesorsen peak sales of greater than $325M world wide. Further, he expects first half 2019 BROADEN data in familial partial lipodystrophy patients is likely to expand the addressable peak volanesorsen opportunity by another $125 million.
LMT Lockheed Martin
$299.44

2.29 (0.77%)

07/19/17
FBCO
07/19/17
NO CHANGE
Target $300
FBCO
Neutral
Lockheed Martin price target raised to $300 from $280 at Credit Suisse
Credit Suisse analyst Robert Spingarn raised his price target for Lockheed Martin to $300 from $280 as he expects shares to grind higher with continued earnings growth, perhaps tempered a little by flattish CF largely due to contract timing. He reiterates a Neutral rating on the shares.
07/19/17
ARGS
07/19/17
NO CHANGE
ARGS
Lockheed Martin price target raised to $320 from $290 at Argus
Argus analyst John Eade increased his price target on Lockheed Martin after the company reported higher than expected Q2 EPS. The analyst notes that U.S. defense spending is rising, while geopolitical tensions are increasing. Calling the stock's valuation attractive, he keeps a Buy rating on the shares.
08/08/17
MSCO
08/08/17
INITIATION
Target $342
MSCO
Overweight
Lockheed Martin initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Rajeev Lalwani initiated Lockheed Martin with an Overweight and a $342 price target saying it has the right balance of segment margin growth, revenue visibility, and leading 5-year CAGR, all supported by the F-35 ramp over the coming years, combined with pension benefits.
07/19/17
WELS
07/19/17
NO CHANGE
WELS
Lockheed Martin weakness overdone, says Wells Fargo
Wells Fargo says that Lockheed Martin's stock dropped after its Q2 results due to disappointment about its 2018 guidance. The firm thinks the decline was overdone, as it expects the stock's P/E to be at least in-line with that of the market, given its belief that U.S. defense budgets are poised to grow. Moreover, Wells says that the company's 2018 guidance actually hasn't changed, and it keeps an Outperform rating on the shares.
RTN Raytheon
$174.42

0.91 (0.52%)

07/11/17
RBCM
07/11/17
NO CHANGE
RBCM
Defense stocks still poised for beat and raise results, says RBC Capital
RBC Capital analyst Matthew McConnell says that defense stocks remain poised for beat and raise results for an extended period, given geopolitical tensions in many parts of the world. He believes that the companies most likely to raise their 2017 in conjunction with their Q2 results are General Dynamics (GD), L3 Technologies (LLL), Raytheon (RTN), and Northrop Grumman (NOC). He recommends Raytheon, General Dynamics, Northrop Grumman, CSRA (CSRA), and KEYW (KEYW).
08/04/17
ARGS
08/04/17
NO CHANGE
ARGS
Raytheon price target raised to $195 from $175 at Argus
Argus analyst John Eade raised his price target on Raytheon after the company reported stronger than expected Q2 results and raised its 2017 guidance. The analyst keeps a Buy rating on the shares.
08/01/17
BOFA
08/01/17
NO CHANGE
Target $200
BOFA
Buy
Raytheon price target raised to $200 from$185 at BofA/Merrill
BofA/Merrill analyst Ronald Epstein raised Raytheon estimates mainly due to strong bookings and a lower tax rate following the strong Q2 report. The analyst said Raytheon increased its bookings guidance on stronger than expected orders and management highlighted new international opportunities are rising. Epstein raised his price target on Raytheon to $200 to reflect increased operating profits and reiterated a Buy rating.
08/08/17
MSCO
08/08/17
INITIATION
Target $188
MSCO
Overweight
Raytheon initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Rajeev Lalwani initiated Raytheon with an Overweight and a $188 price target saying it has leading positions in high demand areas of missile defense and internationally, and optionality around an A-rated balance sheet.
NOC Northrop Grumman
$269.95

0.37 (0.14%)

08/08/17
MSCO
08/08/17
INITIATION
Target $279
MSCO
Equal Weight
Northrop Grumman initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Rajeev Lalwani initiated Northrop Grumman with an Equal Weight and a $279 price target saying its leading revenue profile is offset by light free cash flow yields and margin growth.
03/01/17
SBSH
03/01/17
DOWNGRADE
SBSH
Neutral
Northrop Grumman downgraded to Neutral from Buy at Citi
Citi analyst Jason Gursky downgraded Northrop Grumman (NOC) to Neutral saying Defense stocks are now reaching fair value. The analyst this morning also downgraded to Neutral shares of Huntington Ingalls (HII) and General Dynamics (GD). Gursky keeps Buy ratings on Harris (HRS), L3 Technologies (LLL), Lockheed Martin (LMT) and Raytheon (RTN).
04/18/17
RBCM
04/18/17
NO CHANGE
RBCM
Defense stocks should be bought on any weakness, says RBC Capital
RBC Capital analyst Matthew McConnell,recommends buying defense stocks on any weakness caused by near-term funding uncertainties. The analyst says that the impact of a government shutdown on the sector would be "minor and short-lived," while geopolitical tensions have increased. Publicly traded companies in the space include BAE Systems (BAESY), Boeing (BA), General Dynamics (GD), Lockheed Martin (LMT), Northrop Grumman (NOC), Raytheon (RTN) and United Technologies (UTX).
05/10/17
VERT
05/10/17
UPGRADE
VERT
Buy
Northrop Grumman upgraded to Buy from Hold at Vertical Research
Vertical Research analyst Robert Stallard upgraded Northrop Grumman to Buy from Hold with a $270 price target telling investors defense sector fundamentals remain positive and share underperformance versus peers provides a buying opportunity.
GD General Dynamics
$200.54

-0.6 (-0.30%)

08/08/17
MSCO
08/08/17
INITIATION
Target $185
MSCO
Underweight
General Dynamics initiated with an Underweight at Morgan Stanley
Morgan Stanley analyst Rajeev Lalwani initiated General Dynamics with an Underweight and a $185 price target telling investors he expects Gulfstream may have difficulty sustaining margins given competitive threats.
08/04/17
ARGS
08/04/17
NO CHANGE
ARGS
General Dynamics weakness creates buying opportunity, says Argus
Argus analyst John Eade says that General Dynamics' stock has underperformed over the last quarter, while the company reported higher than expected Q2 EPS. Eade believes that the fact that the company obtains less than 50% of its revenue from the U.S. government makes it more attractive than many of its peers . He thinks the company's recent decision to raise its dividend 1% shows confidence in its outlook. Eades says that the stock's underperformance has created a buying opportunity.
07/12/17
07/12/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Marathon Oil (MRO) initiated with an Equal Weight at Stephens. 2. General Dynamics (GD) initiated with a Buy at Berenberg. 3. Brookfield Renewable (BEP) initiated with a Buy at TD Securities. 4. trivago (TRVG) initiated with a Market Perform at Wells Fargo. 5. Shopify (SHOP) initiated with a Hold at Benchmark. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/12/17
BREN
07/12/17
INITIATION
Target $230
BREN
Buy
General Dynamics initiated with a Buy at Berenberg
Berenberg analyst Charlotte Keyworth initiated General Dynamics with a Buy and a $230 price target.

TODAY'S FREE FLY STORIES

VSAT

ViaSat

$65.44

-0.01 (-0.02%)

08:03
12/11/18
12/11
08:03
12/11/18
08:03
Hot Stocks
ViaSat announces agreement with Sandler Partners »

Viasat announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 13

    Dec

MYE

Myers Industries

$15.83

-0.41 (-2.52%)

08:03
12/11/18
12/11
08:03
12/11/18
08:03
Hot Stocks
Myers Industries promotes Kevin Brackman to CFO »

Myers Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

ASB

Associated Banc-Corp

$21.23

-0.4 (-1.85%)

08:03
12/11/18
12/11
08:03
12/11/18
08:03
Hot Stocks
Associated Banc-Corp subsidiary to acquire branch of Huntington Bancshares »

Associated Banc-Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSE

Trinseo

$47.00

0.61 (1.31%)

08:02
12/11/18
12/11
08:02
12/11/18
08:02
Hot Stocks
Trinseo CEO Chris Pappas to retire in 2019 »

Trinseo announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFX

Equifax

$98.46

-1.11 (-1.11%)

08:02
12/11/18
12/11
08:02
12/11/18
08:02
Hot Stocks
Equifax awarded utility patent for innovative NeuroDecision Technology »

Equifax has received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

SFIX

Stitch Fix

$25.92

-0.42 (-1.59%)

08:02
12/11/18
12/11
08:02
12/11/18
08:02
Recommendations
Stitch Fix analyst commentary  »

Stitch Fix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGM

LogMeln

$86.34

-0.55 (-0.63%)

07:59
12/11/18
12/11
07:59
12/11/18
07:59
Conference/Events
LogMeln management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

FTSI

FTS International

$7.36

-0.41 (-5.28%)

07:59
12/11/18
12/11
07:59
12/11/18
07:59
Upgrade
FTS International rating change  »

FTS International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

URBN

Urban Outfitters

$37.70

0.7 (1.89%)

07:58
12/11/18
12/11
07:58
12/11/18
07:58
Hot Stocks
Urban Outfitters says retail comps up mid single-digit thus far in Q4 »

Urban Outfitters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LC

LendingClub

$2.94

-0.04 (-1.34%)

07:56
12/11/18
12/11
07:56
12/11/18
07:56
Conference/Events
LendingClub management to meet with Craig Hallum »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

HP

Helmerich & Payne

$59.22

-1.54 (-2.53%)

07:56
12/11/18
12/11
07:56
12/11/18
07:56
Upgrade
Helmerich & Payne rating change  »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFIX

Stitch Fix

$25.92

-0.42 (-1.59%)

07:55
12/11/18
12/11
07:55
12/11/18
07:55
Recommendations
Stitch Fix analyst commentary  »

Stitch Fix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVTY

Tivity Health

$27.66

-12.94 (-31.87%)

, NTRI

Nutrisystem

$43.68

9.49 (27.76%)

07:55
12/11/18
12/11
07:55
12/11/18
07:55
Recommendations
Tivity Health, Nutrisystem analyst commentary  »

Tivity Health price…

TVTY

Tivity Health

$27.66

-12.94 (-31.87%)

NTRI

Nutrisystem

$43.68

9.49 (27.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

07:55
12/11/18
12/11
07:55
12/11/18
07:55
Initiation
Roche initiated  »

Roche assumed with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 13

    Dec

  • 24

    Dec

  • 18

    Mar

07:55
12/11/18
12/11
07:55
12/11/18
07:55
General news
U.S. chain store sales rebounded 2.1% in the week ended December 8 »

U.S. chain store sales…

AJG

Arthur J. Gallagher

$74.58

-0.03 (-0.04%)

07:55
12/11/18
12/11
07:55
12/11/18
07:55
Conference/Events
Arthur J. Gallagher to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

BLRX

BioLineRx

$0.66

0.005 (0.76%)

07:55
12/11/18
12/11
07:55
12/11/18
07:55
Conference/Events
BioLineRx to host investor meeting »

Investor Breakfast…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

THS

TreeHouse

$48.95

-1.22 (-2.43%)

07:55
12/11/18
12/11
07:55
12/11/18
07:55
Conference/Events
TreeHouse to host investor day »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

NVO

Novo Nordisk

$45.97

0.59 (1.30%)

07:54
12/11/18
12/11
07:54
12/11/18
07:54
Initiation
Novo Nordisk initiated  »

Novo Nordisk assumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$86.94

-0.22 (-0.25%)

07:53
12/11/18
12/11
07:53
12/11/18
07:53
Initiation
Novartis initiated  »

Novartis assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$145.31

-0.07 (-0.05%)

07:53
12/11/18
12/11
07:53
12/11/18
07:53
Conference/Events
Johnson & Johnson management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

WFT

Weatherford

$0.46

-0.0579 (-11.21%)

07:53
12/11/18
12/11
07:53
12/11/18
07:53
Downgrade
Weatherford rating change  »

Weatherford downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSK

GlaxoSmithKline

$37.68

0.4 (1.07%)

07:52
12/11/18
12/11
07:52
12/11/18
07:52
Initiation
GlaxoSmithKline initiated  »

GlaxoSmithKline assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$38.41

0.23 (0.60%)

07:52
12/11/18
12/11
07:52
12/11/18
07:52
Initiation
AstraZeneca initiated  »

AstraZeneca assumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNSA

Kiniksa

$25.04

3.59 (16.74%)

07:50
12/11/18
12/11
07:50
12/11/18
07:50
Hot Stocks
Kiniksa announces interim data of rilonacept trial, initiates RHAPSODY trial »

Kiniksa announced interim…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.